ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

VINCASAR PFS
Bladder, kidney, and other urologic cancers
Bone and connective tissue cancer
CNS cancers
Leukemias, lymphomas, and other hematologic cancers
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

VINCASAR PFS Rx

Generic Name and Formulations:
Vincristine sulfate 1mg/mL; soln for IV inj; contains mannitol; preservative-free.

Company:
Teva Pharmaceuticals



Therapeutic Use:

Indications for VINCASAR PFS:

In combination with other chemotherapeutic agents for Wilms' tumor.

Adult Dose for VINCASAR PFS:

Usual dose: 1.4mg/m2 IV once weekly. Serum bilirubin >3mg/100mL: reduce dose by 50%.

Children's Dose for VINCASAR PFS:

≤10kg: initially 0.05mg/kg IV once weekly. >10kg: usual dose: 2mg/m2 IV once weekly.

Pharmacological Class:

Antimicrotubule agent.

Contraindications:

Demyelinating form of Charcot-Marie-Tooth syndrome.

Warnings/Precautions:

For IV use only; fatal if given intrathecally. Hepatic dysfunction. Pre-existing neuromuscular disease. Obtain CBCs, platelets before each dose, then periodically. Monitor serum uric acid levels during first 3–4 weeks of treatment. Avoid extravasation. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.

Interactions:

Concomitant radiotherapy through ports that include the liver: not recommended. Potentiated by CYP3A4 enzyme inhibitors (eg, itraconazole). Antagonizes phenytoin. Caution with other neurotoxic or platinum-containing agents. Separate L-asparaginase dose by 12–24hrs (administer after vincristine). Consider discontinuing drugs that cause urinary retention for the first few days following therapy.

Adverse Reactions:

GI upset, paralytic ileus (esp. in children; discontinue temporarily if occurs), polyuria, dysuria, urinary retention, hypertension, hypotension, neuromuscular effects, dyspnea, bronchospasm, alopecia, rash, fever, headache, hypersensitivity reactions, acute uric acid nephropathy.

How Supplied:

Single-use vials (1mL, 2mL)—1

Indications for VINCASAR PFS:

In combination with other chemotherapeutic agents for rhabdomyosarcoma.

Adult Dose for VINCASAR PFS:

Usual dose: 1.4mg/m2 IV once weekly. Serum bilirubin >3mg/100mL: reduce dose by 50%.

Children's Dose for VINCASAR PFS:

≤10kg: initially 0.05mg/kg IV once weekly. >10kg: usual dose: 2mg/m2 IV once weekly.

Pharmacological Class:

Antimicrotubule agent.

Contraindications:

Demyelinating form of Charcot-Marie-Tooth syndrome.

Warnings/Precautions:

For IV use only; fatal if given intrathecally. Hepatic dysfunction. Pre-existing neuromuscular disease. Obtain CBCs, platelets before each dose, then periodically. Monitor serum uric acid levels during first 3–4 weeks of treatment. Avoid extravasation. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.

Interactions:

Concomitant radiotherapy through ports that include the liver: not recommended. Potentiated by CYP3A4 enzyme inhibitors (eg, itraconazole). Antagonizes phenytoin. Caution with other neurotoxic or platinum-containing agents. Separate L-asparaginase dose by 12–24hrs (administer after vincristine). Consider discontinuing drugs that cause urinary retention for the first few days following therapy.

Adverse Reactions:

GI upset, paralytic ileus (esp. in children; discontinue temporarily if occurs), polyuria, dysuria, urinary retention, hypertension, hypotension, neuromuscular effects, dyspnea, bronchospasm, alopecia, rash, fever, headache, hypersensitivity reactions, acute uric acid nephropathy.

How Supplied:

Single-use vials (1mL, 2mL)—1

Indications for VINCASAR PFS:

In combination with other chemotherapeutic agents for neuroblastoma.

Adult Dose for VINCASAR PFS:

Usual dose: 1.4mg/m2 IV once weekly. Serum bilirubin >3mg/100mL: reduce dose by 50%.

Children's Dose for VINCASAR PFS:

≤10kg: initially 0.05mg/kg IV once weekly. >10kg: usual dose: 2mg/m2 IV once weekly.

Pharmacological Class:

Antimicrotubule agent.

Contraindications:

Demyelinating form of Charcot-Marie-Tooth syndrome.

Warnings/Precautions:

For IV use only; fatal if given intrathecally. Hepatic dysfunction. Pre-existing neuromuscular disease. Obtain CBCs, platelets before each dose, then periodically. Monitor serum uric acid levels during first 3–4 weeks of treatment. Avoid extravasation. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.

Interactions:

Concomitant radiotherapy through ports that include the liver: not recommended. Potentiated by CYP3A4 enzyme inhibitors (eg, itraconazole). Antagonizes phenytoin. Caution with other neurotoxic or platinum-containing agents. Separate L-asparaginase dose by 12–24hrs (administer after vincristine). Consider discontinuing drugs that cause urinary retention for the first few days following therapy.

Adverse Reactions:

GI upset, paralytic ileus (esp. in children; discontinue temporarily if occurs), polyuria, dysuria, urinary retention, hypertension, hypotension, neuromuscular effects, dyspnea, bronchospasm, alopecia, rash, fever, headache, hypersensitivity reactions, acute uric acid nephropathy.

How Supplied:

Single-use vials (1mL, 2mL)—1

Indications for VINCASAR PFS:

Acute leukemia. In combination with other chemotherapeutic agents for Hodgkin's disease, non-Hodgkin's malignant lymphomas (lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular, diffuse types).

Adult Dose for VINCASAR PFS:

Usual dose: 1.4mg/m2 IV once weekly. Serum bilirubin >3mg/100mL: reduce dose by 50%.

Children's Dose for VINCASAR PFS:

≤10kg: initially 0.05mg/kg IV once weekly. >10kg: usual dose: 2mg/m2 IV once weekly.

Pharmacological Class:

Antimicrotubule agent.

Contraindications:

Demyelinating form of Charcot-Marie-Tooth syndrome.

Warnings/Precautions:

For IV use only; fatal if given intrathecally. Hepatic dysfunction. Pre-existing neuromuscular disease. Obtain CBCs, platelets before each dose, then periodically. Monitor serum uric acid levels during first 3–4 weeks of treatment. Avoid extravasation. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.

Interactions:

Concomitant radiotherapy through ports that include the liver: not recommended. Potentiated by CYP3A4 enzyme inhibitors (eg, itraconazole). Antagonizes phenytoin. Caution with other neurotoxic or platinum-containing agents. Separate L-asparaginase dose by 12–24hrs (administer after vincristine). Consider discontinuing drugs that cause urinary retention for the first few days following therapy.

Adverse Reactions:

GI upset, paralytic ileus (esp. in children; discontinue temporarily if occurs), polyuria, dysuria, urinary retention, hypertension, hypotension, neuromuscular effects, dyspnea, bronchospasm, alopecia, rash, fever, headache, hypersensitivity reactions, acute uric acid nephropathy.

How Supplied:

Single-use vials (1mL, 2mL)—1

Sign Up for Free e-newsletters